View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Iridex Announces the Publication of an Independent Study Demonstrating...

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of tra...

 PRESS RELEASE

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical ...

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments f...

 PRESS RELEASE

Iridex to Present at the Sidoti Year-End Virtual Investor Conference

Iridex to Present at the Sidoti Year-End Virtual Investor Conference MOUNTAIN VIEW, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Sidoti Year-End Virtual Investor Conference. Management is scheduled to present on Thursday, December 11 at 10:45 am ET. Interested parties may access a live and archived webcast of the presentation on the “Even...

Glaukos Corp: 1 director

A director at Glaukos Corp sold 19,340 shares at 90.000USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Moody's Ratings assigns Baa3 rating to Baxter's senior notes; outlook ...

Moody's Ratings (Moody's) assigned a Baa3 rating to the proposed new senior unsecured notes issuance of Baxter International Inc. (Baxter). At the same time, we assigned a (P)Baa3 rating to Baxter's senior unsecured shelf registration. There are no changes to Baxter's existing ratings including the ...

Baxter International Inc.: Update following downgrade to Baa3

Our credit view of this issuer reflects its elevated financial leverage, with delays in reaching previously stated deleveraging targets.

Moody's Ratings downgrades Baxter to Baa3/P-3; outlook is stable

Moody's Ratings (Moody's) downgraded the ratings of Baxter International Inc. (Baxter) including the senior unsecured ratings to Baa3 from Baa2 and the commercial paper rating to Prime-3 from Prime-2. The outlook is stable. Previously, the ratings were on review for downgrade. This action concludes ...

 PRESS RELEASE

Iridex Reports Third Quarter 2025 Financial Results

Iridex Reports Third Quarter 2025 Financial Results MOUNTAIN VIEW, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Financial Highlights Generated total revenue of $12.5 million, representing growth of 8% year-over-year compared to $11.6 million in the prior year quarterCyclo G6® product fa...

Moody's Ratings reviews Baxter's Baa2/P-2 ratings for downgrade

Moody's Ratings (Moody's) placed the ratings of Baxter International Inc. (Baxter) on review for downgrade. The ratings placed on review include the Baa2 senior unsecured ratings and Prime-2 commercial paper rating. Previously, the outlook was negative. The review is prompted by operating pressure...

 PRESS RELEASE

Iridex to Report Third Quarter 2025 Financial Results on November 11, ...

Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025 MOUNTAIN VIEW, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the third quarter 2025 and provide a business update after the close of trading on Tuesday, November 11, 2025. The Company’s management team will host a corresponding conference call beginning at 2:...

 PRESS RELEASE

Iridex Corporation Receives Formal Notification of Nasdaq Listing Comp...

Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance MOUNTAIN VIEW, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced that it has received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that Iridex has evidenced compliance with the continued listing requirements. As previously reported, on May 14, 2025, Iridex received a noti...

 PRESS RELEASE

Iridex Reports Second Quarter 2025 Financial Results

Iridex Reports Second Quarter 2025 Financial Results MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Financial Highlights Generated total revenue of $13.6 million, representing growth of 7% year-over-year and 14% sequential growth versus the first quarter of 2025Cyclo G6® produ...

Moody's Ratings affirms Baxter at Baa2; revises outlook to negative fr...

Moody's Ratings (Moody's) affirmed Baxter International Inc.'s (Baxter) ratings, including its Baa2 senior unsecured ratings and Prime-2 commercial paper rating. At the same time, we revised the outlook to negative from stable. The ratings affirmation considers Baxter's good scale and diversity as...

 PRESS RELEASE

Iridex to Report Second Quarter 2025 Financial Results on August 12, 2...

Iridex to Report Second Quarter 2025 Financial Results on August 12, 2025 MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the second quarter 2025 and provide a business update after the close of trading on Tuesday, August 12, 2025. The Company’s management team will host a corresponding conference call begin...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: July 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Iridex Announces First Patient Enrolled in an Independent Landmark Inv...

Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, announced today that the first patient has been successfully enrolled in the independent, investigator-led DAME Trial to evaluate the clinical ef...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Baxter International Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 June 2025 in which we reassessed the appropriateness of the ratings in the con...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: June 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch